Hospital Infection Therapeutics Market Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis and Application

Hospital infection therapeutics Market refers to pharmaceutical drugs used to treat hospital nosocomial infections. These infections can occur in hospitals, nursing homes, rehabilitation centers, and other clinical settings and are typically treated with antiviral, antibacterial, and antifungal medications. Vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides, and tigecycline are antibacterial therapeutics inhibiting cell wall synthesis and protein synthesis. Caspofungin and Amphotericin B are antifungal therapeutics that help to prevent hospital-acquired pneumonia, urinary tract infections (UTIs), bloodstream infections, and surgical site infections.

According to the World Health Organization (WHO), for every 100 hospitalized patients, 10 in developed countries and 7 in developing countries acquire at least one healthcare-associated infection. Urinary tract infections are expected to have a significant share of the indications segment and grow significantly. The increasing number of patients with urinary tract infections and ongoing research and development on urinary tract infection treatment are attributed to the growth. Furthermore, the growing elderly population and the prevalence of hospital-acquired infections will drive overall market growth during the forecast period.

Data Bridge Market Research analyses that the hospital infection therapeutics market, which was USD 11.59 billion in 2022, is expected to reach USD 15.26 billion by 2030, at a CAGR of 3.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Request a Sample PDF:  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hospital-infection-therapeutics-market&Shri

Drivers

• Rising prevalence of hospital-acquired diseases

One of the key factors driving the market growth is the rising prevalence of hospital-acquired diseases (HAD). Furthermore, the growing geriatric population, which is more susceptible to such ailments, is driving market expansion. As a result of the deterioration of hygiene facilities in hospitals and other healthcare institutions, hospital-acquired pneumonia and other infections have increased significantly, contributing to the rising demand for hospital infection therapeutics.

• Rising prevalence of infections

According to data published by the New York State Department of Health in November 2019, approximately 160 New York hospitals reported 1,139 colon SSIs out of 19,732 procedures in 2018, resulting in a rate of 5.8 infections per 100 procedures. According to the same source, approximately 15,310 cases of clostridioides difficile infections (CDI) were reported in acute care hospitals in New York in 2018. The high prevalence of hospital-acquired infections is expected to significantly increase the demand for treatment therapies and support the market growth during the forecast period.

Opportunities

• Rising R&D initiatives

The key market players are engaged in extensive R&D initiatives for the development and indication expansion of their already approved HAI treatments. For instance, the FDA approved Allergan plc’s supplemental New Drug Application (sNDA) in February 2018, expanding the approval of Avycaz (ceftazidime and avibactam) to include the treatment of HABP/VABP and hospital-acquired bacterial pneumonia.

Restraints/Challenges

• High cost of clinical trials

Increasing the incidence of treatment-emergent resistance, significant investment required due to high attrition rates in clinical trials, and changing reimbursement policies hampered global market growth.

This hospital infection therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hospital infection therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Browse Complete Report Details-  https://www.databridgemarketresearch.com/reports/global-hospital-infection-therapeutics-market?Shri

Hospital Infection Therapeutics Market Scope

The hospital infection therapeutics market is segmented on the basis of therapeutics, and infections. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapeutics

• Antibacterial Drugs
• Antifungal Drugs
• Antiviral Drugs
• Others

Infections

• Hospital Acquired Pneumonia
• Urinary Tract Infections
• Gastrointestinal Disorders
• Bloodstream Infections
• Surgical Site Infections
• Other Hospital Infections
• Pneumonia
• Surgical Site Infections

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the product portfolios of the top players in the this market
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market
• Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Critical Insights Related to This Market Included in the Report:

• Exclusive graphics and Illustrative SWOT analysis of some of the leading companies in this market
• Value chain analysis of prominent players in the market
• Current trends influencing the dynamics of this market across various geographies
• Recent mergers, acquisitions, collaborations, and partnerships
• Revenue growth of this industry over the forecast period
• Marketing strategy study and growth trends
• Growth driven factor analysis
• Emerging recess segments and region-wise market
• An empirical evaluation of the curve of this market
• Ancient, Present, and Probable scope of the market from both prospect value and volume

Some of the major players operating in the hospital infection therapeutics market are:

• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• GSK plc. (U.K.)
• AstraZeneca (U.K.)
• Johnson & Johnson Services, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Bayer AG (Germany)
• AbbVie Inc. (U.S.)
• Sanofi (France)
• Gilead Sciences, Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Basilea Pharmaceutica Ltd. (Switzerland)
• Spero Therapeutics (U.S.)
• BioSpace (Canada)
• POLYPID (Israel)
• Novartis AG (Switzerland)
• Bellerophon Therapeutics (U.S.)
• Achilles Therapeutics plc. (U.K.)

Browse Detailed Summary of Research Report with TOC:  https://www.databridgemarketresearch.com/toc/?dbmr=global-hospital-infection-therapeutics-market&Shri

Hospital Infection Therapeutics Market Regional Analysis/Insights

The hospital infection therapeutics market is analysed and market size insights and trends are provided by country, therapeutics, and infections as referenced above.

The countries covered in the hospital infection therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hospital infection therapeutics market due to the increasing occurrences of chronic disorders, the rising prevalence of the geriatric population, and the growing number of research and development activities.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the development of healthcare infrastructure and surging levels of investment for the growth of the healthcare system.

Top DBMR Healthcare Reports:        

Global Bipolar Disorder Treatment Market – Industry Trends and Forecast to 2029

Global Diabetic Macular Edema Treatment Market – Industry Trends and Forecast to 2029

Global 3D Cone Beam Computed Tomography (CBCT) Systems Market – Industry Trends and Forecast to 2029

Global Pregnancy Care Products Market – Industry Trends and Forecast to 2029

Global Hair and Care Market – Industry Trends and Forecast to 2030

Global Vascular Stent Market – Industry Trends and Forecast to 2029

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com